The efficacy and safety of perioperative chemotherapy for locally advanced colorectal cancer. - The phase II study-

ABSTRACT: Interventions: 1) All RAS wild-type: 6 courses of cetuximab+mFOLFOX6 or 4 courses of cetuximab+SOX is performed, followed by curative operarion. 2) All RAS mutant-type: 6 courses of FOLFOXIRI or SOXIRI is performed, followed by curative operation. Primary outcome(s): Response rate (judged by enhanced CT and MRI on 12 weeks after initiation of chemotherapy) Study Design: Single arm Non-randomized

DISEASE(S): Locally Advanced Colorectal Cancer

PROVIDER: 2639573 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR